The feasibility study of accelated infliximab infusion from initial administration

The feasibility study of accelated infliximab infusion from initial administration - The feasibility study of accelated infliximab infusion from initial administration

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015297

Enrollment

Registered

2014-10-01

Start date

2012-09-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patient in whom infliximab is indicated(rheumatoid arthritis, Crohn&#39

Interventions

Administration of intravenous infliximab infusion with 60 min accelated procedure for patients who are already successfully treated with usual 2hr infuion without infusion reaction. The tolerable pati

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)infliximab-initial administration case 2)Adequate organ fanction, no hematological disorder 3)Written informed consent

Exclusion criteria

Exclusion criteria: 1)active serious infection 2)active tuberuculosis infection 3)allergy and/or hypersensitivity for mouse-derived protein 4)demyelinating disease(MS) 5)congestive heart failure 6)pregnant, nursing or likelihood of pregnancy woman 7)unable to birth control during and after 6 months from the latest infliximab administration 8)Not suitable for participating in the study for any other reason

Design outcomes

Primary

Measure	Time frame
The incidence of infusion reaction with 60min infliximab accelated infusion	—

Secondary

Measure	Time frame
discontinuous rate due to infusion reaction success rate of rescue by usual 2hrs infusion after occurrence of infusion reaction evaluation of premedication	—

Countries

Japan

Contacts

Public ContactYuichi Takiguchi

Graduate School of Medicine, Chiba University Department of Medical Oncology

takiguchi@faculty.chiba-u.jp043-222-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026